153 related articles for article (PubMed ID: 29935043)
1. The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study.
Maagdenberg H; Bierings MB; van Ommen CH; van der Meer FJM; Appel IM; Tamminga RYJ; le Cessie S; Swen JJ; van der Straaten T; de Boer A; Maitland-van der Zee AH
J Thromb Haemost; 2018 Sep; 16(9):1732-1742. PubMed ID: 29935043
[TBL] [Abstract][Full Text] [Related]
2. Creating a genotype-based dosing algorithm for acenocoumarol steady dose.
Cerezo-Manchado JJ; Rosafalco M; Antón AI; Pérez-Andreu V; Garcia-Barberá N; Martinez AB; Corral J; Vicente V; González-Conejero R; Roldán V
Thromb Haemost; 2013 Jan; 109(1):146-53. PubMed ID: 23196355
[TBL] [Abstract][Full Text] [Related]
3. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
[TBL] [Abstract][Full Text] [Related]
4. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
5. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
Wypasek E; Branicka A; Awsiuk M; Sadowski J; Undas A
Thromb Res; 2014 Sep; 134(3):604-9. PubMed ID: 25042728
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
Stehle S; Kirchheiner J; Lazar A; Fuhr U
Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.
Pérez-Andreu V; Roldán V; López-Fernández MF; Antón AI; Alberca I; Corral J; Montes R; García-Barberá N; Ferrando F; Vicente V; González-Conejero R
J Thromb Haemost; 2010 May; 8(5):1012-7. PubMed ID: 20149073
[TBL] [Abstract][Full Text] [Related]
8. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
[TBL] [Abstract][Full Text] [Related]
9. Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
Wolkanin-Bartnik J; Pogorzelska H; Szperl M; Bartnik A; Koziarek J; Bilinska ZT
Pharmacogenet Genomics; 2013 Nov; 23(11):611-8. PubMed ID: 24108193
[TBL] [Abstract][Full Text] [Related]
10. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.
Cerezo-Manchado JJ; Roldán V; Corral J; Rosafalco M; Antón AI; Padilla J; Vicente V; González-Conejero R
Thromb Haemost; 2016 Jan; 115(1):117-25. PubMed ID: 26538428
[TBL] [Abstract][Full Text] [Related]
11. An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population.
Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Sai Chandran BV; Balachander J; Adithan C
Eur J Clin Pharmacol; 2015 Feb; 71(2):173-81. PubMed ID: 25519826
[TBL] [Abstract][Full Text] [Related]
12. Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.
Smires FZ; Moreau C; Habbal R; Siguret V; Fadili S; Golmard JL; Assaidi A; Beaune P; Loriot MA; Nadifi S
J Clin Pharm Ther; 2012 Oct; 37(5):594-8. PubMed ID: 22486182
[TBL] [Abstract][Full Text] [Related]
13. Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
Ajmi M; Omezzine A; Achour S; Amor D; Hamdouni H; Ismaïl FBF; Rejeb NB; Kechrid CL; Boughzela E; Bouslama A
Eur J Clin Pharmacol; 2018 Jun; 74(6):711-722. PubMed ID: 29479633
[TBL] [Abstract][Full Text] [Related]
14. An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease.
Borobia AM; Lubomirov R; Ramírez E; Lorenzo A; Campos A; Muñoz-Romo R; Fernández-Capitán C; Frías J; Carcas AJ
PLoS One; 2012; 7(7):e41360. PubMed ID: 22911785
[TBL] [Abstract][Full Text] [Related]
15. Acenocoumarol Pharmacogenetic Dosing Algorithms and Their Application in Two Bulgarian Patients with Low Anticoagulant Requirements.
Dimitrova-Karamfilova A; Tzveova R; Chilingirova N; Goranova T; Nachev G; Mitev V; Kaneva R
Biochem Genet; 2015 Dec; 53(11-12):334-50. PubMed ID: 26377995
[TBL] [Abstract][Full Text] [Related]
16. Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis.
Ragia G; Karantza IM; Kelli-Kota E; Kolovou V; Kolovou G; Konstantinides S; Maltezos E; Tavridou A; Tziakas D; Maitland-van der Zee AH; Manolopoulos VG
Drug Metab Pers Ther; 2017 Dec; 32(4):183-190. PubMed ID: 29252193
[TBL] [Abstract][Full Text] [Related]
17. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
18. Effects of age and genetic variations in VKORC1, CYP2C9 and CYP3A4 on the phenprocoumon dose in pediatric patients.
Maagdenberg H; Bierings MB; van Ommen CH; van der Meer FJ; Appel IM; Tamminga RY; Cessie SL; Swen JJ; der Straaten TV; Boer A; Maitland-van der Zee AH
Pharmacogenomics; 2018 Oct; 19(15):1195-1202. PubMed ID: 30207196
[TBL] [Abstract][Full Text] [Related]
19. Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.
Jiménez-Varo E; Cañadas-Garre M; Gutiérrez-Pimentel MJ; Calleja-Hernández MA
Pharmacogenet Genomics; 2014 Oct; 24(10):501-13. PubMed ID: 25089947
[TBL] [Abstract][Full Text] [Related]
20. CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.
Varnai R; Sipeky C; Nagy L; Balogh S; Melegh B
Environ Toxicol Pharmacol; 2017 Dec; 56():282-289. PubMed ID: 29055218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
